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Mitomycin C (MMC) generates free radicals when metabolized. We investigated the eﬀect of melatonin against MMC-induced
genotoxicity in polychromatic erythrocytes and MMC-induced lipid peroxidation in brain and liver homogenates. Rats (N =
36) were classiﬁed into 4 groups: control, melatonin, MMC, and MMC + melatonin. Melatonin and MMC doses of 10mg/kg
and 2mg/kg, respectively, were injected intraperitoneally. Peripheral blood samples were collected at 0, 24, 48, 72, and 96
hours posttreatment and homogenates were obtained at 96 hours posttreatment. The number of micronucleated polychromatic
erythrocytes (MN-PCE) per 1000 PCE was used as a genotoxic marker. Malondialdehyde (MDA) plus 4-hydroxyalkenal (4-HDA)
levels were used as an index of lipid peroxidation. The MMC group showed a signiﬁcant increase in MN-PCE at 24, 48, 72, and
96 hours that was signiﬁcantly reduced with melatonin begin coadministrated. No signiﬁcant diﬀerences were found in lipid
peroxidation. Our results indicate that MMC-induced genotoxicity can be reduced by melatonin.
Copyright © 2009 S. Ortega-Guti´ errez et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Quinonesareamongthemostfrequentlyusedchemotherapy
drugs in the treatment of cancer [1]. Their antitumor
action has been attributed to DNA crosslinking, leading to
inhibition of DNA synthesis and monoadduct formation
and induction of apoptosis and cell death [2–5]. This DNA
d a m a g e ,a sw e l la sd r u g - a s s o c i a t e da d v e r s ee v e n t ss u c h
as cardiovascular and skin toxicity, may be related to the
f o r m a t i o no fr e a c t i v eo x y g e ns p e c i e s( R O S )[ 6, 7].
Mitomycin C (MMC) is a quinone-containing antibiotic
originally isolated from Streptomyces caespitosus in 1958
[8]. MMC has been used to treat a wide variety of solid
tumors. Although current use of MMC is limited, this
agent continues to be a key element in several clinical trials
due to its intrinsic eﬃcacy against many solid tumors and
preferential activity in hypoxic tumoral cells [9]. MMC has
a synergistic eﬀect with radiotherapy via its radiosensitizing
eﬀects, targeting hypoxic cells in radiation resistant tumors
[10, 11]. To achieve its alkylating activity, MMC requires
a bioreductive transformation to form active species that
crosslink DNA [12–14]. Depending on the biotransforma-
tion pathway, metabolism of MMC may generate ROS [15].
WhenROSinteractwithcellsandexceedendogenousantiox-
idant systems, there is indiscriminate damage to biological
macromolecules such as nucleic acids, proteins, and lipids
[16].
Melatonin, N-acetyl-5-methoxytryptamine, is the chief
product of the pineal gland in all vertebrates. Retinal light
exposure reduces the amount of serotonin metabolized to
melatonin via neural pathways connecting the retina to the
pineal gland. Thus, pineal production of melatonin increases
at night, and the amount of melatonin secreted into the
plasma is related to the length of exposure to darkness [17].
Melatonin is involved in the modulation of a variety of
endocrine, neural, and immune functions [17, 18]. Recently,
it has been reported to have signiﬁcant antioxidant activity
[19–22]. Its protection against oxidative damage is enhanced2 Journal of Biomedicine and Biotechnology
by its amphiphilic nature, allowing the melatonin molecule
to readily access all cell compartments, including the nucleus
[23]. Intensive research over the last two decades has shown
the beneﬁcial protective eﬀects of melatonin in a multitude
of pathological processes. Among them, its anticarcinogenic
property has attracted considerable attention [23, 24]. There
is compelling evidence that melatonin may reduce the
growth of established tumors [25].
Since cellular harm produced by MMC is thought to
be at least partially due to a free radical mechanism, and
MMC generates micronuclei-induced genotoxic damage in
animal models [26, 27], the aim of this work was to assess
the genotoxic eﬀect of MMC. These eﬀects were measured as
the number of micronucleated polychromatic erythrocytes
(MN-PCE) from the peripheral blood and the ability of
MMC to induce lipid peroxidation in cerebral and hepatic
homogenates. We also assessed the potential protective
action of melatonin against both micronuclei formation and
lipid peroxidation processes due to MMC.
2.MaterialandMethods
2.1. Chemicals. Analytical grade agents were obtained
from reputable commercial sources. MMC and melatonin
were purchased from Sigma-Aldrich (Madrid, Spain). The
Bioxytech LPO-586 kit for lipid peroxidation was obtained
from Cayman Chemical (Ann Arbor, MI, USA).
2.2. Animal Care and Randomization. Thirty-six Sprague-
Dawley rats weighing 95–100g were purchased from Harlan
Iberica (Barcelona, Spain) and received standard food and
water ad libitum. Animal handling and procedures were in
strictaccordancewiththerecommendationsoftheEuropean
Economic Community Committee (2007/526/CE) for the
care and use of laboratory animals. The experimental proto-
colwasapprovedbyZaragoza’sUniversityEthicalCommittee
for Animal Research (reference PI24/09).
Afteracclimationfortwoweekswitha12-hourlight/dark
cycle (lights on at 0700 and oﬀ at 1900), the rats were divided
to four groups of nine animals in each: control, melatonin,
MMC, and MMC + melatonin. MMC was dissolved in saline
and injected intraperitoneally in a single dose of 2mg/kg.
Melatonin was dissolved in ethanol and thereafter diluted in
saline (ﬁnal concentration of ethanol: 1%) and administered
intraperitoneally in a dose of 10mg/kg. Melatonin treatment
started24hourspriortoMMCadministrationandwasgiven
every 8 hours. Control and MMC groups received the dose
intraperitoneally and with an equal volume of ethanol/saline
solution.
2.3. Tissue Preparation. A5μL peripheral blood sample was
collected from the tail vein of each rat at 0, 24, 48, 72, and 96
hoursafterMMCtreatmentandmountedontwoglassslides.
Afterwards, the extensions were ﬁxed with methanol for 10
minutes. Following ﬁnal blood extractions, at 96 hours, the
animalsweredecapitatedandthebrainandliverwerequickly
removed, washed in cold saline solution (4◦C), and frozen
below −30◦C until MDA + 4-HDA assay was performed.
2.4. Peripheral Blood Micronucleus Test. Peripheral blood
slides were stained with an acridine orange (AO) ﬂuorescent
staining procedure according to Hayashi et al. [28]. A
volume of 0.24mmol AO in phosphate buﬀer (PBS) was
used as the working solution. The methanol-ﬁxed slides
were stained for 3 minutes at room temperature. Each
slide was rinsed twice for three minutes. The excess of
buﬀer was removed with paper. The slides were mounted
with the same buﬀer, covered with a 24 × 60mm cover
slip, and sealed with paraﬃn. Using coded slides, the
analysis of MN-PCE in each slide was done within 1–2
days by two independent researchers, each analyzing one
thousand cells. Utilizing a ﬂuorescent microscope (Zeiss
III-RS), the number of MN-PCE per 1000 polychromatic
erythrocytes (PCE) was counted and, the ratio of PCE to
normochromatic erythrocytes (PCE/NCE) was calculated
(from 300 erythrocytes). Subsequently, the code was broken
and the counts from each evaluator were averaged. With
the AO ﬂuorescent staining procedure, PCE containing RNA
can be identiﬁed by red ﬂuorescence and micronuclei by
yellow-green ﬂuorescence. The number of the MN-PCE was
expressed per 1000PCE.
2.5. Measurement of MDA and 4-HDA. MDA + 4-HDA
levels were used as an index of oxidative breakdown of
lipids in brain and liver tissues [29]. Brieﬂy, samples
were homogenized (1 : 5) (weight/volume) in 20mmol
tris(hydroxymethyl) aminomethane buﬀer (pH 7.4). MDA
+ 4-HDA were determined using the Bioxytech kit. In
the assay, MDA plus 4-HDA reacts with N-methyl-2-
phenylindole, yielding a stable chromophore with a peak
of maximum absorbance at 586nm. Results were expressed
as nmol of MDA + 4-HDA per mg of protein. Protein
concentrations in the tissue homogenates were assessed by
the Bradford method using bovine serum albumin as a
standard [30].
2.6. Statistical Analysis. Results were expressed as means ±
standard errors. Student’s unpaired data t-test and ANOVA
were used for comparison of the means. A P value <. 05 was
considered statistically signiﬁcant.
3. Results
The results of the micronucleus assay obtained in peripheral
blood are illustrated in Figure 1. The number of MN-PCE
at 24, 48, 72, and 96 hours increased signiﬁcantly in the
groups exposed to MMC compared to other groups. No
diﬀerences were observed in the PCE/NCE ratio (Table 1).
The maximal response was observed 48 hours after MMC
administration. When compared to MMC alone, melatonin
signiﬁcantly reduced the number of MMC-induced MN-
PCE in peripheral blood at 24 hours (6.6 ± 0.92 versus
4 ± 0.67; P = .038), 48 hours (14.3 ± 4.77 versus 5.9 ± 0.54;
P = .020), 72 hours (7.1 ± 1.35 versus 3 ± 0.41; P = .04),
and 96 hours (3.5 ± 0.65 versus 1 ± 0.24; P = .03) while
no diﬀerences were appreciated between controls (1.8 ±0.63
versus 1.5 ± 0.43; P = .6).Journal of Biomedicine and Biotechnology 3
Table 1: The ratio of polychromatic erythrocytes/normochromatic erythrocytes (PCE/NCE) in rat peripheral blood after 0, 24, 48, 72, and
96 hours in the four treatment groups
Treatment PCE/NCE ratio (mean ± standard error)
0 hour 24 hours 48 hours 72 hours 96 hours
Control 2.34 ± 0.05 2.13 ± 0.06 2.34 ± 0.02 2.28 ± 0.08 2.22 ± 0.03
aMT 2.35 ± 0.07 2.35 ± 0.07 2.19 ± 0.07 2.23 ± 0.03 2.30 ± 0.03
MMC 2.22 ± 0.06 2.13 ± 0.03 2.11 ± 0.10 2.20 ± 0.06 2.10 ± 0.09
MMC + aMT 1.95 ± 0.04 2.09 ± 0.07 2.05 ± 0.02 2.10 ± 0.07 2.16 ± 0.05
MMC: mitomycin C; aMT: melatonin
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Figure 1: Micronucleated polychromatic erythrocytes (MN-PCE)
per 1000 polychromatic erythrocytes (PCE) in peripheral blood at
0, 24, 48, 72, and 96 hours in four rat groups (n = 9): control,
mitomycin (MMC), melatonin, and MMC + melatonin. Data are
expressed as means ± standard error. P<0.05 versus control (∗)o r
versus MMC (#).
No statistically signiﬁcant diﬀerences of MDA + 4-HDA
were found in brain or liver when the averages of each group
were compared (Figure 2). These results indicate the absence
of lipid peroxidation due to MMC in these organs under our
experimental conditions.
4. Discussion
Our results show that in vivo exposure to MMC induces
genotoxicity as indicated by increases in the number of MN-
PCE at 24, 48, 72, and 96 hours posttreatment. This is
in accordance with previous studies demonstrating MMC-
induced micronuclei [26, 31, 32]. Several in vitro and in vivo
studies have shown that diﬀerent MMC metabolic pathways
result in ROS generation [33–35], and that some MMC
metabolites may form cross-links to adjacent guanines in
DNA [36–39]. Quinones, including MMC, streptonigrin,
and adriamycin, produce ROS as result of one- or two-
electron reduction metabolism [40–42]: ﬁrstly, they or their
one-electron reduction product, semiquinones (SQ•−), may
react with glutathione and protein-SH groups through a
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Figure 2: Malondialdehyde (MDA) plus 4-hydroxyalkenals (4-
HDA) concentrations in brain (a) and liver (b) homogenates from
rats in the presence or absence of treatment with mitomycin C
(MMC) or melatonin. Values are mean ± standard error.
nonenzymatic and/or glutathione transferase reaction; sec-
ondly,SQ•− maygeneratesuperoxideanionradicalsdepend-
ing on the equilibrium potential and the pH [43, 44]; thirdly,
SQ•− and superoxide anion radicals can reduce transition-
metal ions, such as iron and copper, and promote the
hydroxyl radical generation via the Fenton reaction [33, 45].4 Journal of Biomedicine and Biotechnology
On the other hand, our results show that, after 96
hours of MMC treatment, this quinone does not induce
lipid peroxidation in homogenates of brain and liver, as
indicated by its inability to modify signiﬁcantly MDA +
4-HDA concentrations. However, free radicals involve the
micronuclei formation [46] and we have demonstrated that
the antioxidant indoleamine melatonin had a protective
eﬀect against MMC genotoxicity in rat red blood cell
precursors in vivo, suggesting that MMC-induced PCE-
MN elevation may be mediated by free radical generation.
Possible explanations for the lack of lipid peroxidation
induced by MMC could be that the ROS generated as a
consequence of MMC metabolism is insuﬃciently powerful
to generate or propagate lipid peroxidation or that, after 96
hours, MDA + 4-HDA concentrations were reduced by renal
clearance.
Recent interest has focused on the use of molecules that
may partly reduce the side eﬀects of MMC. Several free
radical scavenger agents, such as amifostine and nitroxide,
prevent the cytotoxic damage mediated by MMC in diﬀerent
organs [47–49]. In fact, the United States Food and Drug
Administration (FDA) recently approved amifostine for
use as a cytoprotectant in combination with cyclophos-
phamide and cisplatin for the treatment of advanced ovarian
cancer and nonsmall cell lung cancer [50]. Lipoic acid,
another antioxidant, has also demonstrated an in vivo
dose-dependent protective eﬀect against cyclophosphamide-
induced clastogenicity in the peripheral blood and bone
marrow of rats [51]. Herein, we have extended the evidence
of melatonin as a cell protector, since cotreatment of MMC
and melatonin signiﬁcantly reduced the number of MN-
PCE.Thisisinaccordancewiththeresultsofpreviousstudies
showing a signiﬁcant reduction in micronuclei induction
by diﬀerent genotoxic molecules in peripheral blood and
bone marrow samples [52, 53]. Moreover, melatonin is
also capable of preventing DNA damage induced by not
only mutagens but also diﬀerent alkylating agents such
as 7,12-dimethybenz(α)anthracene, cyclophosphamide, and
benzo(α)pyrene [54].
Melatonin protection against DNA damage and oncoge-
nesisisthoughttobedueinparttoitsantioxidantproperties.
Melatonin, an indoleamine, directly scavenges hydroxyl
radicals, singlet oxygen, and peroxynitrites [19, 55–57],
increases the concentration of endogenous glutathione, and
stimulates the antioxidative enzymes superoxide dismutase
and glutathione peroxidase [58]. Moreover, melatonin has
been shown to prevent iron-induced lipid peroxidation [59].
Thus melatonin may also prevent carcinogenesis [60].
Additionally, once oncogenesis has occurred; melatonin
seems to control cancer growth by means other than its
antioxidant activity. Melatonin might inhibit the uptake and
metabolism of fatty acid signaling molecules that promote
the production of tumoral growth factors [61], reduce
telomerase activity by shortening telomer length [62], and
modulateexpressionoftumorsuppressorgenessuchasTP53
[63]. More recent studies report that melatonin signiﬁcantly
suppresses endothelin-1 converting enzyme activity [64].
Endothelin-1 is a potent vasoconstrictor peptide that is
involved in angiogenesis and cancer growth. This peptide
is usually elevated in the plasma of patient with various
solid tumors and acts to protect cancer cells from apoptosis
and promote endothelial and smooth muscle proliferation
[65]. Finally, the antiestrogenic activity of melatonin also
seems to play a role in its ability to decrease proliferation
in some hormone-responsive tumors. Physiological and
pharmacological concentrations of melatonin exhibited a
growth inhibitory eﬀect on MCF-7 human breast cancer cell
lines [66, 67]. In fact, this eﬀect was particularly manifested
in cancer cell lines possessing the estrogen receptor α (ERα);
this eﬀect seems to be mediated by both membrane (MT1)
and nuclear (RZRα) melatonin receptors [68].
5. Conclusion
Inconclusion,thedatareportedhereinprovideevidencethat
melatonin reduces genotoxicity due to MMC, presumably
due to its antioxidant eﬀects. Based on our observations and
previous results showing that oxidative stress participates in
carcinogenesis and the role of melatonin as an anticarcino-
genic agent with broad bioavailability and lack of side eﬀects
[23], it seems reasonable to propose that cotreatment with
melatonin may be beneﬁcial when used in combination with
MMC for the treatment of some cancers.
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